Company intelligence / Profile preview
Synthonics, Inc.
- Ownership
- Private
- Development stage
- Preclinical
Overview
Synthonics has developed several metal-coordinated pharmaceuticals including zinc-T3 and magnesium-furosemide complexes. They've also worked with RS BioTherapeutics on RSBT-001, a nebulized, semi-synthetic cannabidiolic acid complex for pulmonary inflammation, which showed positive results in a proof-of-concept study[3].
- Therapeutic areas
- GastroenterologyPulmonologyEndocrinologyOncologyNeurologyInfectious Diseases
- Modalities
- Metal Coordinated Pharmaceuticals (MCPs)
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Synthonics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Synthonics, Inc..